CLOs on the Move

AccuraGen Holdings

www.accuragen.com

 
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.accuragen.com
  • 1455 Adams Dr Suite 1015
    Menlo Park, CA USA 94025
  • Phone: 650.618.5028

Executives

Name Title Contact Details

Similar Companies

BioConvergence

BioConvergence is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Technologie BiolActis

Technologie BiolActis Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Neurotrack

Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.

Simplex Sciences

High quality, reliable single-stranded DNA ladders from Simplex Sciences. 10, 20, 50, and 100 base increment ladders are available, with new products coming soon.

Glyscend

Founded in 2014, Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway.